Generating EngTregs to Overcome Key Challenges Associated with the Successful Application of Treg Therapeutics

Time: 1:30 pm
day: Day One | Track A | Morning


  • Engineering abundant T cell populations with stabilized FOXP3 expression to create a scalable and stable Treg phenotype
  • Utilizing an inducible chimeric receptor to provide highly specific and tunable IL-2 signaling support
  • Providing tissue specificity and enhanced regulatory functions through antigen-specific CARs or TCRs